GlassScriptPhysician profile
Leroy C Bell
NPI 1568434181
$20,371.99
in general payments reported to CMS, 2019-2025
18 companies · $9,175 in 2025
The $9,175 reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $1,590 · 2021: $1,104 · 2022: $1,975 · 2023: $2,560 · 2024: $2,480 · 2025: $9,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,650 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,650.00 |
| Education | $428.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $8,726.98 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $2,582.81 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $2,045.38 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,294.88 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,280.95 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,129.22 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $767.44 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $740.59 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $549.89 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $351.78 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $314.08 | 2022-2024 | Perseris, Sublocade |
| Eisai INC. | $240.51 | 2020-2021 | |
| Allergan, INC. | $166.37 | 2019-2020 | |
| Noven Therapeutics, LLC | $58.04 | 2020-2021 | |
| Luye Pharma (USA) LTD. | $45.54 | 2025 | Erzofri Extended-Release |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.53 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.